Table 4.
OAR | α/β | This study (EQD2) | Paradis et al (EQD2)∗6 | Troost et al (EQD2, 9-mo interval)27 | American Radium Society (EQD2)† |
---|---|---|---|---|---|
Spinal cord | 2 | Dmax 60 Gy | D0.1cc <56.25 Gy | Dmax <65 Gy | Dmax <57 Gy |
Esophagus | 3 | Dmax 75-100 Gy | D0.1cc <90.6 Gy | Dmax <100 Gy | V60 <40%, Dmax <100-110 Gy |
Brachial plexus | 2 | Dmax 80-95 Gy | D0.1cc <85 Gy | Dmax <85 Gy | Dmax <85 Gy |
Great vessels | 3 | Dmax 110 – 115 Gy | D0.1cc <123 Gy | Dmax <110 Gy | Dmax <120 Gy |
PBT | 3 | Dmax <80-105 Gy‡ | D0.1cc <90.6 Gy | Dmax <110 Gy | Dmax <110 Gy |
Skin/Chest wall | 2.5 | ALARA | D0.1cc <105 Gy | n/a | n/a |
Heart | 2.5 | ALARA | D0.1cc <85 Gy | Dmean <70 Gy | V40<50% |
Lung | 3 | Individualized | Individualized | Dmean <22 Gy | V20<40% |
Abbreviations: ALARA = as low as reasonably achievable; EQD2 = equieffective dose in 2 Gy fractions; OAR = organs at risk; PBT = proximal bronchial tree.
Dose constraints converted from α/β ratio of 2.5 to the stated α/β ratios in the table to allow ease of comparison; dose constraints derived using a 6- to 12-month interval, with OARs being treated to tolerance in the first treatment.
Dose constraints α/β ratios not quoted in the American Radium Society abstract.
Consensus not reached.